Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RYZ101 Dose Level 1 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RYZ101 Dose Level 1 | DRUG | Dose Level 1 |
| RYZ101 Dose Level 2 | DRUG | Dose Level 2 |
| RYZ101 Dose Level 3 | DRUG | Dose Level 3 |
| RYZ101 Dose Level -1 | DRUG | Dose Level -1 |
| Atezolizumab | DRUG | Atezolizumab |
| Carboplatin | DRUG | Carboplatin |
| Etoposide | DRUG | Etoposide |
RYZ101 Dose Level 1 is an investigational small molecule being studied for the treatment of extensive stage small cell lung cancer (ES-SCLC). It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
RYZ101 Dose Level 1 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY on the stock exchange. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
RYZ101 Dose Level 1 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing trial is actively recruiting participants.
RYZ101 Dose Level 1 is being evaluated in a Phase 1 clinical trial with the identifier NCT05595460. The study, titled 'Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC,' is currently recruiting and aims to enroll 49 participants.
RYZ101 Dose Level 1 refers to a specific dose level of the drug RYZ101. The clinical trial NCT05595460 is studying RYZ101 in combination with standard of care in patients with extensive stage small cell lung cancer.